Hyphens Pharma International Limited (SGX:1J5)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.315
-0.010 (-3.08%)
At close: Mar 4, 2026
12.50%
Market Cap 97.29M
Revenue (ttm) 177.37M
Net Income (ttm) 5.84M
Shares Out 308.87M
EPS (ttm) 0.02
PE Ratio 16.94
Forward PE 8.09
Dividend 0.02 (4.62%)
Ex-Dividend Date May 7, 2025
Volume 76,500
Average Volume 148,610
Open 0.325
Previous Close 0.325
Day's Range 0.315 - 0.325
52-Week Range 0.260 - 0.395
Beta 0.11
RSI 22.04
Earnings Date Feb 26, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Pia... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 474
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 1J5
Full Company Profile

Financial Performance

In 2025, SGXC:1J5's revenue was 177.37 million, a decrease of -9.24% compared to the previous year's 195.42 million. Earnings were 5.84 million, a decrease of -42.67%.

Financial Statements

News

There is no news available yet.